Showing 5621-5630 of 5771 results for "".
- Imprimis to Feature its Cyclosporine/Chondroitin Sulfate and Non-Opioid MKO Melt Formulations at the Upcoming ASCRS Meetinghttps://modernod.com/news/imprimis-to-feature-its-cyclosporine-chondroitin-sulfate-and-non-opioid-mko-melt-formulations-at-the-upcoming-ascrs-meeting/2480266/Imprimis Pharmaceuticals and its ophthalmology-focused ImprimisRx division announced its participation and related physician presentations at the 2018 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting to be held at the Walter E. Washington Convention Center in Washington,
- Dallas Lighthouse for the Blind to Merge With Envisionhttps://modernod.com/news/dallas-lighthouse-for-the-blind-to-merge-with-envision/2480267/Envision announced that it has acquired the Dallas Lighthouse for the Blind. Operations will continue as normal in Dallas, and the Dallas Lighthouse for the Blind name will be retained. Financial terms of the deal were not disclosed. The merger will have positive benefits both in Te
- SightLife Surgical to Acquire the Kamra Inlay From AcuFocushttps://modernod.com/news/sightlife-surgical-to-acquire-the-kamra-inlay/2480269/SightLife Surgical has announced that it will acquire the »Kamra inlay from AcuFocus.
- Zepto Receives Award for Best Capsulotomy Technology 2017https://modernod.com/news/zepto-receives-award-for-best-capsulotomy-technology-2017/2480270/Mynosys Cellular Devices has announced that its flagship automated capsulotomy device, »Zepto, has been selected as the best capsulotomy technology by Cataract and Refrac
- Global Dry Eye Treatment Revenues to Grow to $4.9 Billion by 2022https://modernod.com/news/global-dry-eye-treatment-revenues-to-grow-to-49-billion-by-2022/2480272/Market Scope expects the global dry eye treatments market to grow at a healthy pace through 2022, as 2017 revenues of $3.7 billion climb to $4.9 billion. Revenues will climb most sharply in emerging markets and other developing nations where we forecast double-digit compounded annual growth rates
- Xiidra Approved by Health Canada To Treat the Signs and Symptoms of Dry Eye Diseasehttps://modernod.com/news/xiidra-approved-by-health-canada-to-treat-the-signs-and-symptoms-of-dry-eye-disease/2480273/Shire announced that »Xiidra (lifitegrast ophthalmic solution 5%), a twice-daily eye drop solution indicated for the treatment of the signs and symptoms of dry eye disease i
- Molly Ann Clymerhttps://modernod.com/profiles/molly-ann-clymer/7rBpAP/
- Paul Hammond, OD, FAAOhttps://modernod.com/profiles/paul-hammond-od-faao/OYJpdz/
- Barry Eiden, OD, FAAOhttps://modernod.com/profiles/barry-eiden-od-faao/L0arZE/
- Michael Cymbor, OD, FAAOhttps://modernod.com/profiles/michael-cymbor-od-faao/Lan9rD/